Research Analysts’ Weekly Ratings Updates for Sanara MedTech (SMTI)

A number of research firms have changed their ratings and price targets for Sanara MedTech (NASDAQ: SMTI):

• 8/3/2026 – Sanara MedTech was downgraded by Freedom Capital from “strong-buy” to “hold”.
• 8/1/2026 – Sanara MedTech was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 7/30/2026 – Sanara MedTech was downgraded by Lake Street Capital from “buy” to “hold”. They now have a $35.00 price target on the stock.
• 7/30/2026 – Sanara MedTech was downgraded by HC Wainwright from “buy” to “neutral”. They now have a $35.00 price target on the stock, down from $36.00.
• 7/17/2026 – Sanara MedTech had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 7/4/2026 – Sanara MedTech was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 6/17/2026 – Sanara MedTech was upgraded by Freedom Capital to “strong-buy”.
• 6/10/2026 – Sanara MedTech was upgraded by Zacks Research from “strong sell” to “hold”.

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.